GE HealthCare's StarGuide GX: A New Era in Diagnostic Imaging

2025-11-28 digitalcare

Chicago, Friday, 28 November 2025.
GE HealthCare’s StarGuide GX, a digital 4D SPECT/CT system, received the CE Mark, doubling volume sensitivity and enhancing nuclear medicine capabilities across Europe.

Introduction to StarGuide GX

GE HealthCare has taken a significant leap forward with the StarGuide GX, a digital 4D SPECT/CT system that recently received the CE Mark certification. This system stands out by doubling volume sensitivity and enhancing the capabilities of nuclear medicine imaging. These advancements are crucial for improving diagnostic imaging across Europe, enabling more precise and efficient scans [2][3].

Technological Advancements

The StarGuide GX system integrates cutting-edge technologies including a patented dual collimator detector and NVIDIA RTX accelerated computing. The dual collimator detector design eliminates the need for traditional manual or automated external exchanges, thereby significantly streamlining workflows. Additionally, NVIDIA RTX technology optimizes image reconstruction, reducing the time needed to generate diagnostic images [2]. This system allows clinicians to virtually scan across all energy levels quickly, including investigational alpha emitters like Actinium-225, which is pivotal for advancing nuclear medicine applications [2].

Impact on European Healthcare

With the CE Mark certification, the StarGuide GX can now be marketed across the European Union, marking a pivotal moment for GE HealthCare. The certification ensures compliance with European health, safety, and environmental protection standards, which is essential for its widespread adoption [5][6]. The system’s ability to enhance imaging quality and efficiency is expected to improve patient outcomes significantly, providing clinicians with the tools needed to personalize treatment and improve healthcare delivery [5].

Market and Future Prospects

GE HealthCare plans to showcase the StarGuide GX at the Radiological Society of North America’s Annual Meeting in Chicago, from November 30 to December 3, 2025 [2][7]. This strategic move is expected to bolster the system’s visibility and adoption in both the European and global markets. The increased sensitivity and resolution offered by the StarGuide GX are set to redefine the nuclear medicine landscape, potentially opening new avenues for diagnostic and therapeutic applications [4].

Bronnen

digital health nuclear medicine